Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Rakitzi, Stavroula
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06993662CT.gov The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective. | — | Active Not Recruiting | — | — | — |
NCT05603104CT.gov Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure | — | Recruiting | — | — | — |
NCT04432688CT.gov The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients | — | Completed | — | — | — |
NCT02374567CT.gov Pharmacovigilance in Gerontopsychiatric Patients | — | Terminated | — | — | — |
NCT01143090CT.gov A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder | — | Completed | — | — | — |
NCT01143077CT.gov A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents | — | Completed | — | — | — |
NCT01082263CT.gov Midazolam Drug-Drug Interaction Study With Lurasidone HCl | — | Completed | — | — | — |
NCT01074073CT.gov Lithium Drug-Drug Interaction Study With Lurasidone HCl | — | Completed | — | — | — |
NCT01082250CT.gov The Bioequivalence Of Two Different Lurasidone Formulations In Patients | — | Completed | — | — | — |
NCT00641745CT.gov Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia | — | Completed | — | — | — |
Show 3 more trialsShow fewer
NCT00549718CT.gov Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia | — | Completed | — | — | — |
NCT00183443CT.gov Treatment of Mania Symptoms With Drug Therapy | — | Completed | — | — | — |
NCT00202306CT.gov Indicated Prevention of Psychotic Disorders With Low-dose Lithium | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Schizophrenia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lithium, Elemental (this asset) | Rakitzi, Stavroula | Approved | BB · 68 |
| Xanomeline | European Group for Research In Schizophrenia | P4 | BBB |
| Trospium | European Group for Research In Schizophrenia | P4 | BBB |
| Lurasidone | Aziende Chimiche Riunite Angelini Francesco S.p.A | P4 | BBB |
| Asenapine | Noven Pharmaceuticals, Inc. | P4 | BBB |
| Brexpiprazole | Humanis Saglık Anonim Sirketi | P4 | BBB |
| Bitopertin | Hoffmann-La Roche | P3 | BBB |
| Pyridoxol | Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara | P4 | BBB |
| Raloxifene | Shanghai Mental Health Center | P4 | BBB |
+42 more in the Schizophrenia cohort
Other indications for Lithium, Elemental
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Bipolar I Disorder | — | P4 | BBB · 77 |
| Bipolar Depression | — | P4 | BBB · 75 |
| Manic Bipolar Affective Disorder | — | P4 | BBB · 75 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lithium, Elemental in Schizophrenia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lithium-elemental-schizophrenia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →